Saturday, March 29, 2014 3:50:07 PM
1- revolutionary MJ drug treatment methodology.
2- Emesyl Distribution Contract
3- Emesyl Manfaction Roll out
4- MYEC Application ROI Implementation
Dr. Hensley is a pioneer in the development and marketing of safe and effective therapeutic nutraceutical and homeopathic preparations. He was a founder of the company that launched the Zicam® Cold Remedy, making the product a household name and forever changing the marketing and product placement paradigm for homeopathic drugs in the United States. Dr. Hensley and his team plan to use the same methodologies to revolutionize the treatment of several other common ailments and other chronic diseases.
Intranasal drug delivery - General principles
The nasal cavity's easily accessible, rich vascular plexus permits topically administered drugs to rapidly achieve effective blood levels while avoiding intravenous catheters. This is most effectively accomplished by distributing drug solutions as a mist rather than as larger droplets which may aggregate and run off instead of being absorbed.
Because of this easily accessed vascular bed, nasal administration of medications is emerging as a promising method of delivering medications directly to the blood stream. This method of delivery can eliminate the need for intravenous catheters while still achieving rapid, effective blood levels of the medication administered.
Administering medications via the nasal mucosal offers several advantages:
1 -The rich vascular plexus of the nasal cavity provides a direct route into the blood stream for medications that easily cross mucous membranes.
2 -This direct absorption into the blood stream avoids gastrointestinal destruction and hepatic first pass metabolism (destruction of drugs by liver enzymes) allowing more drug to be cost-effectively, rapidly, and predictably bioavailable than if it were administered orally.
3 -For many IN medications the rates of absorption and plasma concentrations are comparable to intravenous administration, and are typically better than subcutaneous or intramuscular routes.
Note the below is an extremely important advantage:
4 - Ease, convenience and safety: IN drug administration is essentially painless, and does not require sterile technique, intravenous catheters or other invasive devices, and it is immediately and readily available for all patients.
5 -Because the nasal mucosa is nearby the brain, cerebrospinal fluid (CSF) drug concentrations can exceed plasma concentrations. IN administration may rapidly achieve therapeutic brain and spinal cord (CNS) drug concentrations.
Intranasal (IN) medication delivery is simply another option or method to deliver therapeutic medications to the patient’s blood stream to achieve a desired clinical effect. It is a tool in the therapeutic armamentarium just as oral, rectal, sublingual, intramuscular and intravenous delivery methods are also tools to deliver medications.
? Painless
? Ease of use
? No shot needed
? Avoids first pass metabolism - improving bioavailability over oral and rectal doses
? Nose-brain pathway allows direct delivery to the cerebral spinal fluid
? Compliance not an issue - easy and fast to deliver to any patient
In general, medications that consist of small, simple, lipophilic molecules will cross membranes most easily. Having a pH near physiologic helps as well. Finally, if the drug concentration is such that it can be delivered in a reasonable volume to the nose so no runoff into the throat or out the nostril occurs, then more absorption and higher bioavailability is possible.
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM